Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?

Over the last decade, many of the major solid organ cancers have seen improvements in survival due to development of novel therapeutics and corresponding biomarkers that predict treatment efficacy or resistance. In contrast, favorable outcomes remain challenging in pancreatic ductal adenocarcinoma (...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2018-05, Vol.24 (10), p.2241-2250
Main Authors: Krantz, Benjamin A, O'Reilly, Eileen M
Format: Article
Language:English
Subjects:
Adenocarcinoma
Animals
Antineoplastic Agents, Immunological - pharmacology
Antineoplastic Agents, Immunological - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bioassays
Biomarkers
Biomarkers, Tumor
Cancer-Associated Fibroblasts - drug effects
Cancer-Associated Fibroblasts - metabolism
Carcinoma, Pancreatic Ductal - diagnosis
Carcinoma, Pancreatic Ductal - etiology
Carcinoma, Pancreatic Ductal - metabolism
Carcinoma, Pancreatic Ductal - therapy
Clinical trials
Combined Modality Therapy
Decision making
Deoxyribonucleic acid
DNA
Drug development
Drug Resistance, Neoplasm
Exosomes
Humans
Immunotherapy
Induction Chemotherapy
Metabolic Networks and Pathways - drug effects
Molecular Targeted Therapy
Pancreas
Pancreatic Neoplasms
Pancreatic Neoplasms - diagnosis
Pancreatic Neoplasms - etiology
Pancreatic Neoplasms - metabolism
Pancreatic Neoplasms - therapy
Protein Kinase Inhibitors - pharmacology
Protein Kinase Inhibitors - therapeutic use
Treatment Outcome
Tumor cells
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Over the last decade, many of the major solid organ cancers have seen improvements in survival due to development of novel therapeutics and corresponding biomarkers that predict treatment efficacy or resistance. In contrast, favorable outcomes remain challenging in pancreatic ductal adenocarcinoma (PDAC), in part related to the lack of validated biomarkers for patient and treatment selection and thus optimal clinical decision-making. Increasingly, however, therapeutic development for PDAC is accompanied by bioassays to evaluate response and to study mechanism of actions with a corresponding increase in the number of trials in mid to late stage with integrated biomarkers. In addition, blood-based biomarkers that provide a measure of disease activity and allow for minimally invasive tumor analyses are emerging, including circulating tumor DNA, exosomes, and circulating tumor cells. In this article, we review potential biomarkers for currently approved therapies as well as emerging biomarkers for therapeutics under development. .
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.ccr-16-3169